RxDoctor Payments Data

Imran Chaudhary, MD

Interventional Cardiology · Rochester, NYNPI 1154361509

Payments from drug & device makers

$40,613in general payments, 2019–2025

Across 21 payments — averaging $1933.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$39K
  • Johnson & Johnson$444
  • Beone Medicines USA, Inc.$283
  • Daiichi Sankyo Inc.$248
  • E.r. Squibb & Sons, L.L.C.$125
  • AbbVie$125
  • plus $307 from 5 others

What the payments were for

  • Food & beverage$1,73099%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,613 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$89,087
Medicare patients
2,104
Services billed
3,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban325$408,600
Repatha SureclickEvolocumab247$219,164
JardianceEmpagliflozin124$137,610
EntrestoSacubitril/Valsartan81$123,088
XareltoRivaroxaban74$93,833
FarxigaDapagliflozin Propanediol32$46,367
Praluent PenAlirocumab54$41,671
Metoprolol Succinate729$15,344
VascepaIcosapent Ethyl15$13,870
Atorvastatin Calcium931$13,664
Ezetimibe287$9,433
Eplerenone110$7,628
Rosuvastatin Calcium322$6,614
Torsemide280$4,849
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med89$3,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$408,600325 claims
Johnson & JohnsonXarelto$444$93,83374 claims
AstraZenecaFarxiga$39,081$46,36732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →